Cargando…

Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis

AIMS: Age-related macular degeneration (AMD) is the main cause of blindness. Anti-vascular endothelial growth factor is used to prevent further neovascularization due to wet AMD. The purpose of this systematic review was to investigate the effect and protocol of anti-vascular endothelial growth fact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ba, Jun, Peng, Run-Sheng, Xu, Ding, Li, Yan-Hong, Shi, Hui, Wang, Qianyi, Yu, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592052/ https://www.ncbi.nlm.nih.gov/pubmed/26451092 http://dx.doi.org/10.2147/DDDT.S86269

Ejemplares similares

Documentation of adverse events in non-commercial trials of intravitreal injection of anti-VEGF drugs to treat wet age-related macular degeneration (AMD)
por: Reeves, Barnaby C, et al.
Publicado: (2011)

The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
por: Han, Fangyuan, et al.
Publicado: (2022)

Macular Hole Formation After Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration
por: Mukherjee, Chandoshi, et al.
Publicado: (2015)

Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration
por: Davis, R Prince, et al.
Publicado: (2010)

Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study
por: Giancipoli, Ermete, et al.
Publicado: (2018)

Macular Hole Surgery in the Case of Wet Age-Related Macular Degeneration Treated with Intravitreal Aflibercept
por: Nowosielska, Agnieszka
Publicado: (2019)

Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
por: García-Quintanilla, Laura, et al.
Publicado: (2019)

Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration
por: Wen, Joanne C., et al.
Publicado: (2017)

Retinal layers changes in patients with age-related macular degeneration treated with intravitreal anti-VEGF agents
por: Zhou, Dan, et al.
Publicado: (2023)

Results of Intravitreal Anti-VEGF Injection in Choroidal Neovascularization Caused by Pathologies Other Than Age-Related Macular Degeneration
por: Ozveren, Mehmet
Publicado: (2020)

Psychological impact of anti-VEGF treatments for wet macular degeneration—a review
por: Senra, Hugo, et al.
Publicado: (2016)

First-Year Outcomes of Cataract Surgery Combined with Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration
por: Sül, Sabahattin, et al.
Publicado: (2019)

Risk factors for breakthrough vitreous hemorrhage after intravitreal anti-VEGF injection in age-related macular degeneration with submacular hemorrhage
por: Shin, Yong-Il, et al.
Publicado: (2018)

Choriocapillaris Vascular Density Changes: Healthy vs. Advanced Exudative Age-Related Macular Degeneration Previously Treated with Multiple Anti-VEGF Intravitreal Injections
por: Savastano, Maria Cristina, et al.
Publicado: (2021)

Brolucizumab Intravitreal Injections for Wet Age-Related Macular Degeneration: Real-Life Study on a Cohort of Italian Patients
por: Gesualdo, Carlo, et al.
Publicado: (2023)

Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration
por: Ferrone, Philip J, et al.
Publicado: (2014)

The Efficacy of Intravitreal Aflibercept in Submacular Hemorrhage Secondary to Wet Age-related Macular Degeneration
por: Shin, Kyung-Hoon, et al.
Publicado: (2016)

Subretinal Neovascular Membrane in Wet Age-Related Macular Degeneration Managed With Intravitreal Ranibizumab
por: Sharma, Tanishq S, et al.
Publicado: (2021)

Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration
por: Yamashita, Mariko, et al.
Publicado: (2018)

Intraocular inflammatory cytokines in patients with neovascular age-related macular degeneration before and after initiation of intravitreal injection of anti-VEGF inhibitor
por: Sato, Tomohito, et al.
Publicado: (2018)

Atrophy of retinal vessels in neovascular age-related macular degeneration following long-term treatment with 20 intravitreal anti-VEGF injections
por: Resch, Miklós D., et al.
Publicado: (2022)

Outcome of 5-Year Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Using “Treat and Extend” Regimen
por: Jaki Mekjavic, Polona, et al.
Publicado: (2018)

Use of nepafenac (Nevanac(®)) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections
por: Chen, Eric, et al.
Publicado: (2010)

Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study
por: Ogura, Yuichiro, et al.
Publicado: (2015)

Effects of Intravitreal Ranibizumab Injection on Chinese Patients with Wet Age-Related Macular Degeneration: 5-Year Follow-Up Results
por: Lu, Yingyi, et al.
Publicado: (2016)

Acute macular neuroretinopathy associated with intravitreal anti-VEGF injection: A case report
por: Radwan, Loubna M., et al.
Publicado: (2022)

Examination of Inner Retinal Layers in Unilateral Wet Age-Related Macular Degeneration Treated with Anti-VEGF, Compared to Fellow Untreated Eyes
por: Wichrowska, Małgorzata, et al.
Publicado: (2022)

Incidence of Retinal Pigment Epithelial Tears and Associated Risk Factors After Treatment of Age-Related Macular Degeneration with Intravitreal Anti-VEGF Injections§
por: Empeslidis, Theodoros, et al.
Publicado: (2014)

Adding a Corticosteroid or Switching to Another Anti-VEGF in Insufficiently Responsive Wet Age-Related Macular Degeneration
por: Kaya, Cagdas, et al.
Publicado: (2019)

Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration
por: Chen, Rui, et al.
Publicado: (2020)

Three-Month Results of Brolucizumab Intravitreal Therapy in Patients with Wet Age-Related Macular Degeneration
por: Michalska-Małecka, Katarzyna, et al.
Publicado: (2021)

Polymorphic nanobody crystals as long‐acting intravitreal therapy for wet age‐related macular degeneration
por: Zhu, Shuqian, et al.
Publicado: (2023)

Changes in Retinal Nerve Fiber Layer Thickness after Two Intravitreal Bevacizumab Injections for Wet Type Age-related Macular Degeneration
por: Entezari, Morteza, et al.
Publicado: (2014)

Inflammatory Complications of Intravitreal Anti-VEGF Injections
por: Cox, Jacob T., et al.
Publicado: (2021)

Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept
por: Stewart, Michael W
Publicado: (2012)

Long-term effects of intravitreal bevacizumab and aflibercept on intraocular pressure in wet age-related macular degeneration
por: Kähkönen, Mikael, et al.
Publicado: (2021)

Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis
por: Hernandez, Luis, et al.
Publicado: (2018)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou, Stamatina A, et al.
Publicado: (2017)

Prevalence of Polypoidal Choroidal Vasculopathy in Eyes with Neovascular Age-Related Macular Degeneration Resistant to Intravitreal Anti-VEGF Treatment
por: Menteş, Jale, et al.
Publicado: (2022)

Comparison of dexamethasone intravitreal implant with intravitreal anti-VEGF injections for the treatment of macular edema secondary to branch retinal vein occlusion: A meta-analysis
por: Ji, Kaibao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pajfnmeb6rv0ht48lnc5soap0f